Hualan Co., Ltd. announced that the 19th meeting of the 6th board of directors reviewed and passed a number of proposals. It was agreed to adjust the investment matters of the wholly-owned subsidiary Hainan Lingqing Shuzhi Pharmaceutical Technology Co., Ltd. in Wuxi Natural Constant Technology Co., Ltd.; due to the cancellation of the repurchase of shares in 2025, it is proposed to change the company's registered capital, revise the “Articles of Association”, and apply for commercial and commercial change registration. The bill needs to be submitted to the 2026 Second Extraordinary Shareholders' Meeting for consideration; the “Interbank Bond Market Debt Financing Instrument Information Disclosure Management System”; the company is scheduled to hold the 2026 Second Extraordinary Shareholders' Meeting on August 27, 2026.

Hualan Co., Ltd. announced that the 19th meeting of the 6th board of directors reviewed and passed a number of proposals. It was agreed to adjust the investment matters of the wholly-owned subsidiary Hainan Lingqing Shuzhi Pharmaceutical Technology Co., Ltd. in Wuxi Natural Constant Technology Co., Ltd.; due to the cancellation of the repurchase of shares in 2025, it is proposed to change the company's registered capital, revise the “Articles of Association”, and apply for commercial and commercial change registration. The bill needs to be submitted to the 2026 Second Extraordinary Shareholders' Meeting for consideration; the “Interbank Bond Market Debt Financing Instrument Information Disclosure Management System”; the company is scheduled to hold the 2026 Second Extraordinary Shareholders' Meeting on August 27, 2026.